Form 4: Cytek Biosciences CFO Patrik Jeanmonod Reports Stock Transactions
SEC Form 4
Cytek Biosciences CFO Patrik Jeanmonod reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On March 11, 2024, Patrik Jeanmonod, CFO of Cytek Biosciences, engaged in transactions involving the company's common stock.
- Jeanmonod vested 4,908 restricted stock units (RSUs), each representing a contingent right to receive one share of Cytek's common stock.
- Simultaneously, 1,912 shares were withheld by Cytek to satisfy tax obligations related to the RSU vesting at a price of $7.22.
- Following these transactions, Jeanmonod directly owns 97,465 shares of Cytek Biosciences.
- He also owns 44,182 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions, with no inherent positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of stock transactions by a company insider, providing transparency to investors regarding the executive's holdings and recent activities.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect routine executive compensation and tax obligations.
Key Dates
| Date | Description |
|---|---|
| 03/11/2024 | Date of RSU vesting and tax withholding. |
| 03/13/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.